229 related articles for article (PubMed ID: 34434191)
21. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.
Schmid H; Schneidawind C; Jahnke S; Kettemann F; Secker KA; Duerr-Stoerzer S; Keppeler H; Kanz L; Savage PB; Schneidawind D
Front Immunol; 2018; 9():1817. PubMed ID: 30127790
[TBL] [Abstract][Full Text] [Related]
22. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
[TBL] [Abstract][Full Text] [Related]
23. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
24. Intestinal microbes affect phenotypes and functions of invariant natural killer T cells in mice.
Wingender G; Stepniak D; Krebs P; Lin L; McBride S; Wei B; Braun J; Mazmanian SK; Kronenberg M
Gastroenterology; 2012 Aug; 143(2):418-28. PubMed ID: 22522092
[TBL] [Abstract][Full Text] [Related]
25. Altered invariant natural killer T cell subsets and its functions in patients with oral squamous cell carcinoma.
Singh AK; Shukla NK; Das SN
Scand J Immunol; 2013 Nov; 78(5):468-77. PubMed ID: 23980793
[TBL] [Abstract][Full Text] [Related]
26. Invariant natural killer T cells: bridging innate and adaptive immunity.
Van Kaer L; Parekh VV; Wu L
Cell Tissue Res; 2011 Jan; 343(1):43-55. PubMed ID: 20734065
[TBL] [Abstract][Full Text] [Related]
27. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
28. Strategy of lipid recognition by invariant natural killer T cells: 'one for all and all for one'.
Mallevaey T; Selvanantham T
Immunology; 2012 Jul; 136(3):273-82. PubMed ID: 22671023
[TBL] [Abstract][Full Text] [Related]
29. High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity.
Erkers T; Xie BJ; Kenyon LJ; Smith B; Rieck M; Jensen KP; Ji X; Basina M; Strober S; Negrin RS; Maecker HT; Meyer EH
Blood; 2020 Mar; 135(11):814-825. PubMed ID: 31935280
[TBL] [Abstract][Full Text] [Related]
30. Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.
Lam PY; Nissen MD; Mattarollo SR
Front Immunol; 2017; 8():1355. PubMed ID: 29109728
[TBL] [Abstract][Full Text] [Related]
31. Stress-elicited glucocorticoid receptor signaling upregulates TIGIT in innate-like invariant T lymphocytes.
Rudak PT; Gangireddy R; Choi J; Burhan AM; Summers KL; Jackson DN; Inoue W; Haeryfar SMM
Brain Behav Immun; 2019 Aug; 80():793-804. PubMed ID: 31108170
[TBL] [Abstract][Full Text] [Related]
32. Dicer-dependent microRNA pathway controls invariant NKT cell development.
Fedeli M; Napolitano A; Wong MP; Marcais A; de Lalla C; Colucci F; Merkenschlager M; Dellabona P; Casorati G
J Immunol; 2009 Aug; 183(4):2506-12. PubMed ID: 19625646
[TBL] [Abstract][Full Text] [Related]
33. Brief homogeneous TCR signals instruct common iNKT progenitors whose effector diversification is characterized by subsequent cytokine signaling.
Bortoluzzi S; Dashtsoodol N; Engleitner T; Drees C; Helmrath S; Mir J; Toska A; Flossdorf M; Öllinger R; Solovey M; Colomé-Tatché M; Kalfaoglu B; Ono M; Buch T; Ammon T; Rad R; Schmidt-Supprian M
Immunity; 2021 Nov; 54(11):2497-2513.e9. PubMed ID: 34562377
[TBL] [Abstract][Full Text] [Related]
34. Costimulatory activation of murine invariant natural killer T cells by toll-like receptor agonists.
Kulkarni RR; Villanueva AI; Elawadli I; Jayanth P; Read LR; Haeryfar SM; Sharif S
Cell Immunol; 2012; 277(1-2):33-43. PubMed ID: 22795895
[TBL] [Abstract][Full Text] [Related]
35. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
36. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.
Croudace JE; Curbishley SM; Mura M; Willcox CR; Illarionov PA; Besra GS; Adams DH; Lammas DA
BMC Immunol; 2008 Dec; 9():71. PubMed ID: 19055753
[TBL] [Abstract][Full Text] [Related]
37. Exploiting CD1-restricted T cells for clinical benefit.
Exley MA; Dellabona P; Casorati G
Mol Immunol; 2021 Apr; 132():126-131. PubMed ID: 33582549
[TBL] [Abstract][Full Text] [Related]
38. Cytokine Output of Adipocyte-iNKT Cell Interplay Is Skewed by a Lipid-Rich Microenvironment.
van Eijkeren RJ; Morris I; Borgman A; Markovska A; Kalkhoven E
Front Endocrinol (Lausanne); 2020; 11():479. PubMed ID: 32849273
[TBL] [Abstract][Full Text] [Related]
39. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
Front Immunol; 2018; 9():1990. PubMed ID: 30298063
[TBL] [Abstract][Full Text] [Related]
40. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
